Amphastar Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030

Updated on 12/06/2023

Stock Rating
14
Price Target
$66.00
Consensus
Outperform
Upside
13.30%
Analysts
0
Stock Rating
14
Upside
13.30%
Analysts
0
Price Target
$66.00

Amphastar Pharmaceuticals Stock Forecast and Price Target

Amphastar Pharmaceuticals has an average price target of $66.00 recently offered by notable experts for 2023, which would represent a potential upside of approximately 13.3% from the last closing price in December, 2023 if reached. This potential increase is based on a high estimate of $71.00 and a low estimate of $63.00. If you are not interested in AMPH stock, you may be interested in its competitors.

$66.00

13.30% Upside

Outperform
Outperform

Amphastar Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030

In the last three years, Price for Amphastar Pharmaceuticals has grown by 447.22%, going from $10.46 to $57.25. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach $77.59 – an increase of 35.53%. Over the next eight years, experts anticipate that Fair Value growth for Amphastar Pharmaceuticals will be 152.45%.

2023 Fair Value Forecast
$77.59
2024 Fair Value Forecast
$95.90
2025 Fair Value Forecast
$111.59
2026 Fair Value Forecast
$144.14
2027 Fair Value Forecast
$188.89
2028 Fair Value Forecast
$150.90
2029 Fair Value Forecast
$140.29
2030 Fair Value Forecast
$144.52
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
LLY Stock Forecast Eli Lilly & Co Outperform 16
$589.25 Buy/Sell $594.01 10.31%
NOVO B Stock Forecast Novo Nordisk A/S Outperform 10
kr678.50 Buy/Sell kr696.07 14.22%
SUNPHARMA Stock Forecast Sun Pharmaceutical Industries Buy 18
Rp1.24k Buy/Sell Rp845.39 3.20%
TEVA Stock Forecast Teva Pharmaceutical Industries Outperform 12
$9.83 Buy/Sell $12.04 9.36%
HALO Stock Forecast Halozyme Therapeutics Inc Outperform 11
$39.97 Buy/Sell $51.90 25.09%

Amphastar Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030

In the last three years, Revenue for Amphastar Pharmaceuticals has grown by 54.79%, going from $322.36M to $498.99M. In the coming year, analysts are expecting an increase in Revenue, predicting it will reach $632.40M – an increase of 26.74%. Over the next eight years, experts anticipate that Revenue growth for Amphastar Pharmaceuticals will be 100.75%.

2023 Rev Forecast
$0.63B
2024 Rev Forecast
$0.79B
2025 Rev Forecast
$0.86B
2026 Rev Forecast
$0.99B
2027 Rev Forecast
$1.21B
2028 Rev Forecast
$1.05B
2029 Rev Forecast
$0.99B
2030 Rev Forecast
$1.00B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
HIK Stock Forecast Hikma Pharmaceuticals PLC Outperform 18
£18.03 Buy/Sell £28.13 54.02%
PBH Stock Forecast Prestige Consumer Healthcare Buy 16
$59.17 Buy/Sell $71.50 18.30%
BHC Stock Forecast Bausch Health Companies Outperform 15
$7.17 Buy/Sell $34.09 11.58%

Amphastar Pharmaceuticals Dividend per Share Forecast for 2023 - 2025 - 2030

2023 DPS Forecast
$0.00
2024 DPS Forecast
$0.00
2025 DPS Forecast
$0.00
2026 DPS Forecast
$0.00
2027 DPS Forecast
$0.00
2028 DPS Forecast
$0.00
2029 DPS Forecast
$0.00
2030 DPS Forecast
$0.00
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
SUPN Stock Forecast Supernus Pharmaceuticals Outperform 16
$26.78 Buy/Sell $41.00 54.97%
AMRX Stock Forecast Amneal Pharmaceuticals Outperform 16
$4.55 Buy/Sell $6.30 31.87%
ANIP Stock Forecast ANI Pharmaceuticals Buy 13
$48.72 Buy/Sell $71.00 43.68%

Amphastar Pharmaceuticals Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last three years, Amphastar Pharmaceuticals's Free Cash Flow has grown, increasing from $200.00k to $61.72M – an increase of 30760.00%. 0 analysts predict Amphastar Pharmaceuticals's Free Cash Flow will decrease by 50.56% in the next year, reaching $30.51M. By 2030, professionals predict that Amphastar Pharmaceuticals's Free Cash Flow will decrease by 19.65%, to $49.59M.

2023 FCF Forecast
$0.03B
2024 FCF Forecast
$0.04B
2025 FCF Forecast
$0.05B
2026 FCF Forecast
$0.06B
2027 FCF Forecast
$0.05B
2028 FCF Forecast
$0.04B
2029 FCF Forecast
$0.05B
2030 FCF Forecast
$0.05B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ZEAL Stock Forecast Zealand Pharma A/S Buy 8
kr350.60 Buy/Sell kr241.83 11.52%
XERS Stock Forecast Xeris Biopharma Holdings Buy 6
$1.92 Buy/Sell $0.00 134.38%
EBS Stock Forecast Emergent BioSolutions Hold 16
$2.53 Buy/Sell $5.00 97.63%

Amphastar Pharmaceuticals Net Income Forecast for 2023 - 2025 - 2030

In the last three years, Amphastar Pharmaceuticals's Net Income has increased by 86.74%, going from $48.94M to $91.39M. In the next year, analysts are expecting an increase in Net Income, predicting it will reach $170.10M – an increase of 86.13%. The Amphastar Pharmaceuticals forecast is for Net Income to reach $276.67M or grow by 202.74%.

2023 NI Forecast
$0.17B
2024 NI Forecast
$0.18B
2025 NI Forecast
$0.21B
2026 NI Forecast
$0.28B
2027 NI Forecast
$0.36B
2028 NI Forecast
$0.29B
2029 NI Forecast
$0.27B
2030 NI Forecast
$0.28B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ASRT Stock Forecast Assertio Holdings Buy 8
$1.10 Buy/Sell $6.75 263.64%
EGRX Stock Forecast Eagle Pharmaceuticals Inc-DE - 14
$5.94 Buy/Sell $50.50 -100.00%
OPNT Stock Forecast Opiant Pharmaceuticals Buy 10
$20.89 Buy/Sell $43.00 -100.00%

Amphastar Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030

Amphastar Pharmaceuticals's EBITDA has increased by 634.53% In the last three years, going from $18.07M to $132.73M. In the next year, analysts expect EBITDA to reach $225.75M – an increase of 70.08%. For the next eight years, the forecast is for EBITDA to grow by 204.22%.

2023 EBITDA Forecast
$0.23B
2024 EBITDA Forecast
$0.30B
2025 EBITDA Forecast
$0.33B
2026 EBITDA Forecast
$0.38B
2027 EBITDA Forecast
$0.51B
2028 EBITDA Forecast
$0.43B
2029 EBITDA Forecast
$0.40B
2030 EBITDA Forecast
$0.40B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
LCI Stock Forecast Lannett Company Hold 10
$0.62 Buy/Sell $2.25 262.90%
ACOR Stock Forecast Acorda Therapeutics Inc - 5
$12.49 Buy/Sell $5.00 -100.00%
ADMP Stock Forecast Adamis Pharmaceuticals - 8
$0.61 Buy/Sell $1.50 -40.98%

Amphastar Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030

In the last three years, Amphastar Pharmaceuticals's EBIT has grown, increasing from $-40.00k to $107.50M – a growth of 268850.00%. The next year looks promising for Amphastar Pharmaceuticals, with analysts predicting EBIT of $218.60M – an increase of 103.35%. Over the next eight years, experts anticipate that Amphastar Pharmaceuticals's EBIT will grow at a rate of 243.73%.

2023 EBIT Forecast
$0.22B
2024 EBIT Forecast
$0.26B
2025 EBIT Forecast
$0.29B
2026 EBIT Forecast
$0.37B
2027 EBIT Forecast
$0.47B
2028 EBIT Forecast
$0.39B
2029 EBIT Forecast
$0.36B
2030 EBIT Forecast
$0.37B

Amphastar Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last three years, EPS for Amphastar Pharmaceuticals has grown by 447.22%, going from $0.36 to $1.97. In the coming year, analysts are expecting an increase in EPS, predicting it will reach $2.67 – an increase of 35.53%. Over the next eight years, experts anticipate that EPS growth for Amphastar Pharmaceuticals will be 152.45%.

2023 EPS Forecast
$2.67
2024 EPS Forecast
$3.30
2025 EPS Forecast
$3.84
2026 EPS Forecast
$4.96
2027 EPS Forecast
$6.50
2028 EPS Forecast
$5.19
2029 EPS Forecast
$4.83
2030 EPS Forecast
$4.97